霊長類用ウイルスベクターの世界市場

霊長類用ウイルスベクターの世界市場は2030年までに2億6,530万米ドルに達する見込み

2024年に1億5,630万米ドルと推定される霊長類用ウイルスベクターの世界市場は、2030年には2億6,530万米ドルに達し、分析期間2024-2030年のCAGRは9.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるアデノウイルスベクターは、CAGR 11.6%を記録し、分析期間終了時には1億90万米ドルに達すると予測されます。アデノ関連ベクターセグメントの成長率は、分析期間中CAGR 7.4%と推定されます。

米国市場は4,260万米ドルと推定される一方、中国はCAGR 13.0％で成長すると予測される

米国の霊長類用ウイルスベクター市場は、2024年に4,260万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR13.0％を引きずる形で、2030年までに予測市場規模5,480万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.3％と8.2％と予測されています。欧州では、ドイツがCAGR 7.3%で成長すると予測されています。

世界の「霊長類用ウイルスベクター」市場- 主要動向と促進要因のまとめ

霊長類をベースとした生物医学研究においてウイルスベクターが人気を集めているのはなぜか？

高度な生物医学および神経学的研究における非ヒト霊長類（NHP）の使用の増加により、高効率ウイルスベクターの需要が加速しています。これらのベクターは、宿主細胞に遺伝物質を送達するための不可欠なツールであり、研究者が遺伝子発現を正確に操作することを可能にします。NHPの文脈では、ウイルスベクターは、複雑な脳機能、神経変性疾患、ヒトに酷似した認知行動の研究に使用されています。神経解剖学や生理学の点でNHPはヒトに類似しているため、トランスレーショナルリサーチの理想的なモデルとなっています。アデノ随伴ウイルス（AAV）、レンチウイルス、単純ヘルペスウイルスは、その安定した発現、高い感染性、免疫原性反応の減少により、最も一般的に使用されているベクターの一つです。最近、オプトジェネティクスや遺伝子治療アプローチへの関心が急増していることから、ウイルスベクターは、NHPを用いた前臨床研究において不可欠な道具としての役割をさらに確実なものにしています。これらのモデルにおいて、特定の脳領域や遺伝子配列を標的とする際に要求される精度は、ニューロン特異的プロモーターや組織対向性を持つオーダーメイドのベクターへのシフトを促しています。その結果、学術機関、製薬会社、バイオテクノロジー企業は、霊長類研究に合わせたウイルスベクター開発に多額の投資を行っています。

規制の変化と倫理基準は情勢にどのような影響を与えているのか？

霊長類以外へのウイルスベクターの応用が拡大するにつれ、科学的完全性と倫理遵守の両方を確保するために、世界の規制の枠組みが進化しています。NIH、EMA、FDAなどの規制機関は、実験室での非ヒト霊長類とウイルスベクターの使用を規定する厳しいガイドラインを導入しています。これには、バイオセーフティ、ベクター封じ込め、動物福祉に関する詳細なプロトコルが含まれます。倫理的配慮もまた、研究デザインを形成する上で重要な役割を果たしており、利害関係者を最小限の侵襲と洗練されたベクター送達システムへと押しやっています。3Rの原則-置換、削減、改良-は、より少ない投与量でより高い導入効率を提供するウイルスベクターの選択に影響を及ぼし、被験動物への全体的な負担を軽減しています。同時に、神経科学者、ウイルス学者、生物工学者の学際的な共同研究が、より効果的で倫理的に健全なベクター設計の革新を促しています。霊長類に特化したウイルスベクターリポジトリやオープンアクセスプラットフォームの確立も、世界的に標準化を促進しています。さらに、データ報告や倫理審査プロセスの透明性の向上は、研究者がNHP研究のためにウイルスベクターを選択する際の選択に影響を与え始めており、この分野における説明責任と持続可能性の向上へのシフトを示しています。

どのような技術革新がこの分野を前進させているのか？

技術革新は、霊長類以外の研究へのウイルスベクターの使用において何が可能かを劇的に再定義しています。CRISPRベースのゲノム編集やシングルセルシーケンシングなどの高度なベクター工学技術は、より的を絞った効率的な遺伝子操作を可能にしています。定向進化によって設計されたカスタマイズ可能なAAVキャプシドは現在、脳深部構造内であっても特定の神経細胞集団を選択的に標的とすることを可能にしています。高スループット・スクリーニング技術により、特異性が向上し、免疫反応が最小化された新規ベクター血清型の発見が加速されています。同時に、懸濁培養でのスケーラブルな生産やクロマトグラフィーによる精製など、ベクター製造プロセスの改善により、大規模研究に適した臨床グレードのベクターの製造が可能になってきています。さらに、定位注射、集束超音波を介した送達、低侵襲のカテーテルベースのシステムなど、送達方法の革新により、霊長類におけるベクター導入の精度が大幅に向上しています。ベクターの挙動を予測し、投与量を最適化し、標的外効果を評価するために、AI主導のモデリングツールも採用されています。こうした進歩は、基礎研究と応用調査範囲を広げるだけでなく、動物モデルとヒト臨床試験とのギャップを埋めるトランスレーショナル研究に道を開くものでもあります。

霊長類用ウイルスベクター市場の急成長の原動力は？

霊長類用ウイルスベクター市場の成長は、進化する研究パラダイム、技術の進歩、エンドユーザーの需要と密接に結びついたいくつかの要因によってもたらされています。主な促進要因は、従来のげっ歯類モデルでは不十分な神経変性疾患のモデル化において、NHPへの依存度が高まっていることです。これにより、複雑な脳ネットワークの機能的研究を促進できるウイルスベクターのような精密なツールに対する強い需要が生まれています。製薬会社やバイオテクノロジー企業による遺伝子治療パイプラインの拡大も大きなきっかけとなっています。これらの企業は、ヒト試験に進む前に霊長類モデルでしっかりとした前臨床検証を行う必要があるからです。学術機関や政府の研究機関も、神経科学や行動学研究のための資金提供を強化しており、そのためにはNHPでウイルスベクターを使用する必要があります。個別化医療とバイオマーカー発見が重視されるようになり、ウイルスベクターが可能にする高度なin vivoモデルの必要性がさらに高まっています。さらに、オープンサイエンスとデータ共有の動向は、標準化された高性能のNHP用ベクターの作製に重点を置く共同コンソーシアムにつながっています。最後に、霊長類に特異的な免疫抑制戦略の進歩により、ベクターの拒絶反応が最小限に抑えられ、これらのツールが長期的な研究においてより実行可能で信頼できるものとなっています。これらの要因が相まって、世界市場は急速な拡大と多様化の段階へと向かっています。

セグメント

ベクタータイプ（アデノウイルスベクター、アデノ随伴ベクター、レトロウイルスベクター、レンチウイルスベクター、その他のベクタータイプ）、治療領域（遺伝子疾患、感染症、腫瘍疾患、その他の治療領域）、用途（遺伝子治療、ワクチン研究）、最終用途（製薬・バイオテクノロジー企業、学術・研究機関）

調査対象企業の例（合計 41注目）

• 4D Molecular Therapeutics
• Andelyn Biosciences
• Barinthus Biotherapeutics
• Beacon Therapeutics
• Biovian Oy
• Catalent Pharma Solutions
• Charles River Laboratories
• CRISPR Therapeutics
• FinVector Oy
• Fujifilm Diosynth Biotechnologies
• Genezen
• Lonza Group AG
• Merck KGaA
• Neuracle Genetics Inc.
• Oxford Biomedica
• REGENXBIO Inc.
• Rocket Pharmaceuticals, Inc.
• SIRION Biotech GmbH
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Viral Vectors for Non-Human Primates Market to Reach US$265.3 Million by 2030

The global market for Viral Vectors for Non-Human Primates estimated at US$156.3 Million in the year 2024, is expected to reach US$265.3 Million by 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Adenoviral Vectors, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$100.9 Million by the end of the analysis period. Growth in the Adeno-Associated Vectors segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Million While China is Forecast to Grow at 13.0% CAGR

The Viral Vectors for Non-Human Primates market in the U.S. is estimated at US$42.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$54.8 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.3% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global "Viral Vectors for Non-Human Primates" Market - Key Trends & Drivers Summarized

Why Are Viral Vectors Gaining Traction in Primate-Based Biomedical Research?

The increasing use of non-human primates (NHPs) in advanced biomedical and neurological research is accelerating the demand for highly efficient viral vectors. These vectors are indispensable tools for delivering genetic material into host cells, enabling researchers to manipulate gene expression with precision. In the context of NHPs, viral vectors are used for studying complex brain functions, neurodegenerative diseases, and cognitive behaviors that closely mimic those in humans. The species similarity of NHPs to humans in terms of neuroanatomy and physiology makes them ideal models for translational research. Adeno-associated viruses (AAVs), lentiviruses, and herpes simplex viruses are among the most commonly used vectors due to their stable expression, high infectivity, and reduced immunogenic responses. The recent surge in interest for optogenetics and gene therapy approaches further cements the role of viral vectors as essential instruments in preclinical studies involving NHPs. The precision required in targeting specific brain regions or genetic sequences in these models has prompted a shift toward tailor-made vectors with neuron-specific promoters and tissue tropism. Consequently, academic institutions, pharmaceutical companies, and biotech firms are investing heavily in viral vector development tailored to primate research.

How Are Regulatory Shifts and Ethical Standards Influencing the Landscape?

As viral vector applications in non-human primates expand, global regulatory frameworks are evolving to ensure both scientific integrity and ethical compliance. Regulatory bodies such as the NIH, EMA, and FDA have introduced stringent guidelines that govern the use of NHPs and viral vectors in laboratory settings. These include detailed protocols for biosafety, vector containment, and animal welfare. Ethical considerations are also playing a significant role in shaping research design, pushing stakeholders toward minimal invasiveness and refined vector delivery systems. The 3Rs principle-Replacement, Reduction, and Refinement-is influencing the selection of viral vectors that offer higher transduction efficiency with lower doses, reducing the overall burden on animal subjects. Concurrently, cross-disciplinary collaborations between neuroscientists, virologists, and bioengineers are catalyzing innovations in vector design that are both more effective and ethically sound. The establishment of primate-specific viral vector repositories and open-access platforms is also promoting standardized practices globally. Additionally, increased transparency in data reporting and ethical review processes has begun influencing the choices researchers make when selecting viral vectors for NHP studies, indicating a shift toward greater accountability and sustainability in the field.

What Technological Breakthroughs Are Pushing This Field Forward?

Technological innovations are dramatically redefining what is possible in the use of viral vectors for non-human primate research. Advanced vector engineering techniques, such as CRISPR-based genome editing and single-cell sequencing, are enabling more targeted and efficient genetic manipulations. Customizable AAV capsids designed through directed evolution now allow for selective targeting of specific neuronal populations, even within deep brain structures. High-throughput screening technologies have accelerated the discovery of novel vector serotypes with enhanced specificity and minimized immune responses. Simultaneously, improvements in vector manufacturing processes-such as scalable production in suspension cultures and purification via chromatography-are making it feasible to produce clinical-grade vectors suitable for large-scale studies. Moreover, innovations in delivery methods, including stereotactic injection, focused ultrasound-mediated delivery, and minimally invasive catheter-based systems, have significantly improved the precision of vector deployment in primates. AI-driven modeling tools are also being employed to predict vector behavior, optimize dosages, and assess off-target effects. These advances are not only expanding the scope of basic and applied research but are also paving the way for translational studies that could bridge the gap between animal models and human clinical trials.

What’s Powering the Surge in the Viral Vectors for Non-Human Primates Market?

The growth in the viral vectors for non-human primates market is driven by several factors closely tied to evolving research paradigms, technological advancements, and end-user demands. A primary driver is the increasing reliance on NHPs in neurodegenerative disease modeling, where traditional rodent models fall short. This has created a strong demand for precision tools like viral vectors that can facilitate functional studies of complex brain networks. The expansion of gene therapy pipelines by pharmaceutical and biotech companies is another major catalyst, as these firms require robust preclinical validation in primate models before progressing to human trials. Academic and government research institutions are also ramping up funding for neuroscience and behavioral research that necessitates the use of viral vectors in NHPs. There is a rising emphasis on personalized medicine and biomarker discovery, which further fuels the need for advanced in vivo models enabled by viral vectors. Additionally, the trend toward open science and data sharing has led to collaborative consortia that focus on creating standardized, high-performance vectors for NHP use. Lastly, advancements in primate-specific immunosuppressive strategies have minimized vector rejection, making these tools more viable and reliable in long-term studies. Together, these factors are converging to push the global market into a phase of rapid expansion and diversification.

SCOPE OF STUDY:

The report analyzes the Viral Vectors for Non-Human Primates market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors, Other Vector Types); Therapeutic Area (Genetic Disorders, Infectious Diseases, Oncological Disorders, Other Therapeutic Areas); Application (Gene Therapy, Vaccine Research); End-Use (Pharma & Biotech Companies, Academic & Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• 4D Molecular Therapeutics
• Andelyn Biosciences
• Barinthus Biotherapeutics
• Beacon Therapeutics
• Biovian Oy
• Catalent Pharma Solutions
• Charles River Laboratories
• CRISPR Therapeutics
• FinVector Oy
• Fujifilm Diosynth Biotechnologies
• Genezen
• Lonza Group AG
• Merck KGaA
• Neuracle Genetics Inc.
• Oxford Biomedica
• REGENXBIO Inc.
• Rocket Pharmaceuticals, Inc.
• SIRION Biotech GmbH
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Viral Vectors for Non-Human Primates - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increased Use of NHP Models in Neurological Research Spurs Demand for Viral Vectors
  • Rising Investment in Gene Therapy Expands Addressable Market Opportunity
  • Regulatory Push for Ethical NHP Use Strengthens Business Case for Viral Vector Customization
  • Advances in Vector Tropism Tailoring Drives Adoption in Preclinical Studies
  • Growing Complexity of Disease Models Accelerates Demand for Novel Vector Systems
  • Outsourcing Trends in Biopharma R&D Propel Growth in Specialized Vector Services
  • Shift Towards Non-Invasive Delivery Methods Spurs Innovation in Viral Vector Design
  • Collaborative Research Ecosystems Sustain Growth in Translational NHP Research
  • Heightened Focus on Zoonotic Safety Issues Throws the Spotlight on Regulatory Compliance
  • Integration of AI in Vector Optimization Drives Efficiency Gains
  • Emerging Applications in Vaccine R&D Expand Market Scope for Viral Vectors
  • Funding Initiatives by Global Health Agencies Strengthen Long-Term Market Outlook
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Viral Vectors for Non-Human Primates Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Adeno-Associated Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Adeno-Associated Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Adeno-Associated Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Lentiviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Lentiviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Lentiviral Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Vector Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• JAPAN
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• CHINA
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• EUROPE
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• FRANCE
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• GERMANY
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 143: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• INDIA
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 218: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
• AFRICA
  • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030

IV. COMPETITION